REGN Stock Ownership Activity

REGENERON PHARMACEUTICALS 13F holders

2 value investing gurus have made changes to the REGENERON PHARMACEUTICALS (REGN) position according to the gurus' latest SEC quarterly report(s). REGN has been bought (as a new position) by 2 guru(s)

Which gurus or hedge funds are buying REGN now?

According to the latest SEC filing(s) REGENERON PHARMACEUTICALS (REGN) has been bought by 2 gurus: Ole Andreas Halvorsen - Viking Global Investors (new buy) and Mason Hawkins - Longleaf Partners (new buy).

To see more about who is investing in REGENERON PHARMACEUTICALS (REGN), please go to the REGN ownership page.

History
Name
Company
%
Activity
Share
Change
% change to
Portfolio
% of
Portfolio
2014 Q4 (2 results)
David M. Polen
Polen Capital Management
-1.74%
-9,609
-0.08%
4.58%
Ole Andreas Halvorsen
Viking Global Investors
-100.00%
-1,080,682
-1.79%
0.00%
Current price: $483.07 17.75% AVG reported price*: $410.25
2014 Q3 (2 results)
David M. Polen
Polen Capital Management
+164.59%
+281,515
+2.78%
3.67%
Ole Andreas Halvorsen
Viking Global Investors
-63.53%
-1,882,774
-2.73%
0.00%
Current price: $483.07 33.99% AVG reported price*: $360.52
2014 Q2 (2 results)
Ole Andreas Halvorsen
Viking Global Investors
+181.75%
+1,796,956
+2.36%
3.44%
David M. Polen
Polen Capital Management
-4.82%
-9,938
-0.07%
1.21%
Current price: $483.07 71.02% AVG reported price*: $282.47
2014 Q1 (2 results)
Ole Andreas Halvorsen
Viking Global Investors
buy
+762,555
+1.32%
0.96%
David M. Polen
Polen Capital Management
+12,416.45%
+217,412
+1.41%
1.42%
Current price: $483.07 60.87% AVG reported price*: $300.28
2013 Q2 (1 result)
David M. Polen
Polen Capital Management
buy
+1,751
+0.01%
0.01%
Current price: $483.07 114.68% Reported price*: $225.01
9 of 58

Shares, change to shares, sold shares - split-adjusted.

Reported price - this doesn't represent the actual buy or sell price.
It is the split-adjusted price of the security as of the last day of the reported period.

Value or Price - If the security is completely sold out, we show the reported value (or price) prior to the actual period.